降低风险输卵管卵巢切除术与BRCA1/2致病性变异女性乳腺癌风险的关联
该病例系列纳入乳腺癌家族登记中498个BRCA1和378个BRCA2致病性变异家族,采用生存分析评估RRSO与乳腺癌风险的时变关联。结果显示术后5年内RRSO与乳腺癌风险降低相关(BRCA1 HR 0.28,BRCA2 HR 0.19),5年后关联减弱;40岁行RRSO者至70岁累积乳腺癌风险在BRCA1携带者中低于未行RRSO者。
要点
- BRCA1/2携带者RRSO术后5年内乳腺癌风险显著降低。
- 术后5年后RRSO与乳腺癌风险的关联减弱,BRCA2接近无效。
- BRCA1携带者40岁行RRSO至70岁累积乳腺癌风险低于未行RRSO者。
核心结论
- RRSO与BRCA1和BRCA2致病性变异携带者术后5年内乳腺癌风险降低相关,BRCA1携带者还显示与长期累积乳腺癌风险的关联。
研究设计与样本
- 病例系列,纳入乳腺癌家族登记1996至2000年入组的498个BRCA1家族(2650人)和378个BRCA2家族(1925人)。
- 采用专为评估RRSO与乳腺癌风险时变关联设计的生存分析方法,并校正其他潜在偏倚。
主要发现
- 术后5年内RRSO与乳腺癌风险降低相关:BRCA1 HR 0.28(95%CI 0.10-0.63),BRCA2 HR 0.19(95%CI 0.06-0.71)。
- 术后5年后相应HR减弱:BRCA1 HR 0.64(95%CI 0.38-0.97),BRCA2 HR 0.99(95%CI 0.84-1.00)。
- 40岁行RRSO者至70岁乳腺癌病因特异性累积风险:BRCA1为49.7%(95%CI 40.0-60.3),BRCA2为52.7%(95%CI 47.9-58.7)。
- 未行RRSO者至70岁累积风险:BRCA1为61.0%(95%CI 56.7-66.0),BRCA2为54.0%(95%CI 49.3-60.1)。
临床怎么用
- RRSO的主要指征仍为预防卵巢癌,评估其与乳腺癌风险的关联有助于指导RRSO的使用和时机决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Women with pathogenic variants in BRCA1 and BRCA2 are at high risk of developing breast and ovarian cancers. They usually undergo intensive cancer surveillance and may also consider surgical interventions, such as risk-reducing mastectomy or risk-reducing salpingo-oophorectomy (RRSO). Risk-reducing salpingo-oophorectomy has been shown to reduce ovarian cancer risk, but its association with breast cancer risk is less clear. OBJECTIVE: To assess the association of RRSO with the risk of breast cancer in women with BRCA1 and BRCA2 pathogenic variants. DESIGN, SETTING, AND PARTICIPANTS: This case series included families enrolled in the Breast Cancer Family Registry between 1996 and 2000 that carried an inherited pathogenic variant in BRCA1 (498 families) or BRCA2 (378 families). A survival analysis approach was used that was designed specifically to assess the time-varying association of RRSO with breast cancer risk and accounting for other potential biases. Data were analyzed from August 2019 to November 2020. EXPOSURE: Risk-reducing salpingo-oophorectomy. MAIN OUTCOMES AND MEASURES: In all analyses, the primary end point was the time to a first primary breast cancer. RESULTS: A total of 876 families were evaluated, including 498 with BRCA1 (2650 individuals; mean [SD] event age, 55.8 [19.1] years; 437 White probands [87.8%]) and 378 with BRCA2 (1925 individuals; mean [SD] event age, 57.0 [18.6] years; 299 White probands [79.1%]). Risk-reducing salpingo-oophorectomy was associated with a reduced risk of breast cancer for BRCA1 and BRCA2 pathogenic variant carriers within 5 years after surgery (hazard ratios [HRs], 0.28 [95% CI, 0.10-0.63] and 0.19 [95% CI, 0.06-0.71], respectively), whereas the corresponding HRs were weaker after 5 years postsurgery (HRs, 0.64 [95% CI, 0.38-0.97] and 0.99 [95% CI; 0.84-1.00], respectively). For BRCA1 and BRCA2 pathogenic variant carriers who underwent RRSO at age 40 years, the cause-specific cumulative risk of breast cancer was 49.7% (95% CI, 40.0-60.3) and 52.7% (95% CI, 47.9-58.7) by age 70 years, respectively, compared with 61.0% (95% CI, 56.7-66.0) and 54.0% (95% CI, 49.3-60.1), respectively, for women without RRSO. CONCLUSIONS AND RELEVANCE: Although the primary indication for RRSO is the prevention of ovarian cancer, it is also critical to assess its association with breast cancer risk in order to guide clinical decision-making about RRSO use and timing. The results of this case series suggest a reduced risk of breast cancer associated with RRSO in the immediate 5 years after surgery in women carrying BRCA1 and BRCA2 pathogenic variants, and a longer-term association with cumulative breast cancer risk in women carrying BRCA1 pathogenic variants.
引用
- Choi YH, Terry MB, Daly MB, et al. Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants. JAMA Oncol. 2021. PMID: 33630024. doi:10.1001/jamaoncol.2020.7995
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。